Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Avricore Health Inc V.AVCR

Alternate Symbol(s): AVCRF

Technology Diagnostics & Research Information Technology Services

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.

TSXV:AVCR - Post by User

Avricore Health Inc

Bullboard Posts

Post by kingposton Apr 26, 2016 7:06pm

136 Views

Post# 24812790

Generic Insulin being developed in china with Lannett JV..

Lannett Company (NYSE:LCI) announces plans to co-develop a generic insulin pharmaceutical product for sale in the U.S. with its strategic partner in China, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Lannett, who will have exclusive marketing rights to the late-stage candidate, will take over the remaining clinical and regulatory work to support an FDA filing.

According to IMS, the U.S. insulin market is greater than $21B.